Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

References

• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87. doi:10.1016/j.pathol.2017.09.006
   PubMed Web of Science ®Google Scholar
• Ok CY, Medeiros LJ. High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. Pathology. 2020;52(1):68–77. doi:10.1016/j.pathol.2019.09.008
   PubMed Web of Science ®Google Scholar
• Assi R, Masri N, Abou Dalle I, El-Cheikh J, Ghanem H, Bazarbachi A. Polatuzumab vedotin: current role and future applications in the treatment of patients with diffuse large B-cell lymphoma. Clin Hematol Int. 2021;3(1):21. doi:10.2991/chi.k.210305.001
   PubMedGoogle Scholar
• Hafeez U, Parakh S, Gan HK, Scott AM. Antibody–drug conjugates for cancer therapy. Molecules. 2020;25(20):4764. doi:10.3390/molecules25204764
   PubMed Web of Science ®Google Scholar
• Bai R, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem. 1990;265(28):17141–17149. doi:10.1016/S0021-9258(17)44880-0
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–784. doi:10.1038/nbt832
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465. doi:10.1182/blood-2003-01-0039
   PubMed Web of Science ®Google Scholar
• Solimando AG, Annese T, Tamma R, et al. New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers. 2020;12(7):1869. doi:10.3390/cancers12071869
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Armitage JO, editor. My treatment approach to patients with diffuse large B-cell lymphoma. Mayo Clinic Proceedings. Elsevier; 2012.
   Google Scholar
• Melchardt T, Egle A, Greil R. How I treat diffuse large B-cell lymphoma. ESMO open. 2023;8(1):100750. doi:10.1016/j.esmoop.2022.100750
   PubMed Web of Science ®Google Scholar
• Howlett C, Snedecor SJ, Landsburg DJ, et al. Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis. Br J Haematol. 2015;170(4):504–514. doi:10.1111/bjh.13463
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617. doi:10.1016/S2352-3026(18)30177-7
   PubMed Web of Science ®Google Scholar
• Novo M, Castellino A, Nicolosi M, et al. High-grade B-cell lymphoma: how to diagnose and treat. Expert Rev Hematol. 2019;12(7):497–506. doi:10.1080/17474086.2019.1624157
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17(12):3776–3785. doi:10.1200/JCO.1999.17.12.3776
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117–122. doi:10.1182/blood.V71.1.117.117
   PubMed Web of Science ®Google Scholar
• Velasquez W, McLaughlin P, Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12(6):1169–1176. doi:10.1200/JCO.1994.12.6.1169
   PubMed Web of Science ®Google Scholar
• Girouard C, Dufresne J, Imire K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin’s lymphoma prior to autologous bone marrow transplantation. Ann Oncol. 1997;8(7):675–680. doi:10.1023/A:1008294725992
   PubMed Web of Science ®Google Scholar
• Caballero M, Amigo M, Hernández J, et al. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin’s lymphomas. Ann Hematol. 1997;74(2):79–82. doi:10.1007/s002770050261
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684–3688. doi:10.1182/blood-2003-11-3911
   PubMed Web of Science ®Google Scholar
• Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma. Cancer Invest. 2006;24(6):593–600. doi:10.1080/07357900600814490
   PubMed Web of Science ®Google Scholar
• Jermann M, Jost L, Taverna C, et al. Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004;15(3):511–516. doi:10.1093/annonc/mdh093
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MCA, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–715. doi:10.1016/S1470-2045(15)70128-2
   PubMed Web of Science ®Google Scholar
• Hatake K, Kinoshita T, Terui Y, et al. A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed/refractory b-cell non-Hodgkin lymphoma: a comparison with non-Japanese DCS4968g study. Am Soci Clin Oncol. 2016;34(15_suppl):e19070. doi:10.1200/JCO.2016.34.15_suppl.e19070
   Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–e265. doi:10.1016/S2352-3026(19)30026-2
   PubMed Web of Science ®Google Scholar
• Phillips T, Brunvand M, Chen A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib/II study. Blood. 2016;128(22):622. doi:10.1182/blood.V128.22.622.622
   Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155. doi:10.1200/JCO.19.00172
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363. doi:10.1056/NEJMoa2115304
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Kolibaba KS, Tilly H, et al. Polatuzumab vedotin combined with obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (G-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): updated results of a phase Ib/II study. Blood. 2017;130:4120.
   Web of Science ®Google Scholar
• Gouni S, Rosenthal AC, Crombie JL, et al. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Adv. 2022;6(9):2757–2762. doi:10.1182/bloodadvances.2021006801
   PubMed Web of Science ®Google Scholar
• Shemesh CS, Agarwal P, Lu T, et al. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2020;85(5):831–842. doi:10.1007/s00280-020-04054-8
   PubMed Web of Science ®Google Scholar
• Lynch RC, Poh C, Ujjani CS, et al. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Adv. 2023;7(11):2449–2458. doi:10.1182/bloodadvances.2022009145
   PubMed Web of Science ®Google Scholar
• Song Y, Tilly H, Rai S, et al. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood. 2023;141(16):1971–1981.
   PubMed Web of Science ®Google Scholar
• Vodicka P, Benesova K, Janikova A, et al. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world. Eur J Haematol. 2022;109(2):162–165. doi:10.1111/ejh.13784
   PubMed Web of Science ®Google Scholar